0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-17E

IL-17E

Brief Information

Name:Interleukin-25
Target Synonym:IL17E,IL-25,IL-17E,Interleukin-17E,Interleukin 17E,Interleukin 25
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IL5-H52H9-ELISA
 IL-17E ELISA

Immobilized Human IL-17 RB, Fc Tag (Cat. No. ILB-H5251) at 5 μg/mL (100 μL/well) can bind Human IL-17E, His Tag (Cat. No. IL5-H52H9) with a linear range of 0.2-3 ng/mL (QC tested).

IL5-H82E1-MALS-HPLC
IL-17E MALS images

The purity of Biotinylated Human IL-17E Protein, His,Avitag (Cat. No. IL5-H82E1) is more than 85% and the molecular weight of this protein is around 50-60 kDa verified by SEC-MALS.

Synonym Name

IL-17E,IL-25,Interleukin-25

Background

Interleukin 25 (IL25) is also known as Interleukin-17E (IL-17E), is a distinct member of the IL17 cytokine family comprised of at least six members sharing a conserved cysteine-knot structure but divergent at the N-terminus. IL-25 is secreted by type 2 helper T cells (Th2) and mast cells. IL25 can induce NF-κB activation, and stimulate the production of IL8. Both this cytokine and IL17B are ligands for the cytokine receptor IL17RB. IL-25 induces the production of other cytokines, including IL-4, IL-5 and IL-13 in multiple tissues, which stimulate the expansion of eosinophils. This cytokine is an important molecule controlling immunity of the gut and has been implicated in chronic inflammation associated with the gastrointestinal tract. IL-25 can kill some types of breast cancer cells.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
XKH-001(Xinkanghe Biomedical) XKH-001 Phase 2 Clinical Suzhou Kanova Biopharmaceutical Co Ltd, Beijing Kanova Biomedical Technology Co Ltd Allergic asthma; Asthma; Inflammation Details
XKH-001(Xinkanghe Biomedical) XKH-001 Phase 2 Clinical Suzhou Kanova Biopharmaceutical Co Ltd, Beijing Kanova Biomedical Technology Co Ltd Allergic asthma; Asthma; Inflammation Details

This web search service is supported by Google Inc.

totop

Laisser un message